Ciprofloxacin for rhinoscleroma and ozena

Borgstein, Johannes; Sada, Eduardo; Cortés, Ricardo

doi:10.1016/0140-6736(93)91329-k

Cited by 29 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BORGSTEIN et al(1993), reported that 89% of culture of the biopsy of the lesion was negative two months after the use of ciprofloxacin for four weeks, and after six months clinical improvement was significant and the relapse rate was low 11 . However, the duration of antibiotic therapy with ciprofloxacin has not been established, different author recommend using for six weeks to six months or longer, until repeated cultures and histological examination are negative 30 .…”

Section: Discussionmentioning

confidence: 99%

“…In vitro, these bacteria are inhibited by clinically achievable concentrations of amoxicillin -clavulanate, chloramphenicol, trimethoprim -sulfamethoxazole, cephalosporins, streptomycin, tetracyclines and ciprofloxacin 32 . However, in vivo, antibiotics with demonstrated efficacy are streptomycin, doxycycline, tetracycline, rifampicin, second-and third-generation cephalosporin, sulfonamides, clofazimine, ciprofloxacin 11 and ofloxacin 31 . Because K.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rhinoscleroma: eight Peruvian cases

Maguiña¹,

Cortez-Escalante

Osores-Plenge³

et al. 2006

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Rhinoscleroma is a rare infection in developed countries; although, it is reported with some frequency in poorer regions such as Central Africa, Central and South America, Eastern and Central Europe, Middle East, India and Indonesia. Nowadays, rhinoscleroma may be erroneously diagnosed as mucocutaneos leishmaniasis, leprosy, paracoccidioidomycosis, rhinosporidiasis, late syphilis, neoplasic diseases or other upper airway diseases. From 1996 to 2003, we diagnosed rhinoscleroma in eight patients attended in the Dermatologic and Transmitted Diseases service of "Cayetano Heredia" National Hospital, in Lima, Peru. The patients presented airway structural alterations producing nasopharyngeal, oropharyngeal and, in one patient, laryngeal stenosis. Biopsy samples revealed large vacuolated macrophages (Mikulicz cells) in all patients. Ciprofloxacin 500 mg bid for four to 12 weeks was used in seven patients and oxytetracycline 500 mg qid for six weeks in one patient. After follow-up for six to 12 months the patients did not show active infection or relapse, however, all of them presented some degree of upper airway stenosis. These cases are reported because of the difficulty diagnosing the disease and the success of antibiotic treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Rhinoscleroma: eight Peruvian cases

Maguiña¹,

Cortez-Escalante

Osores-Plenge³

et al. 2006

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

show abstract

“…Despite its high overall cost, ciprofloxacin for four weeks was found to be more cost-effective and clinically efficacious than the standard six-month combination of rifampin and co-trimoxazole normally used at one institution in an endemic area. 12 Increased compliance, due to shorter duration of treatment, twice-daily dosing and a low sideeffect profile, makes ciprofloxicin an appealing drug of choice. Moreover, ciprofloxacin achieves superior tissue penetration and is concentrated within macrophages.…”

Section: Clinical Recordmentioning

confidence: 99%

Klebsiella rhinoscleromatis of the membranous nasal septum

Chan

Spiegel

2007

J. Laryngol. Otol.

View full text Add to dashboard Cite

Rhinoscleroma is a chronic, infectious, granulomatous disease that may present with mass lesions in the respiratory tract anywhere from the nose to the trachea. The nose is involved in 95-100 per cent of cases. There are three stages of the disease: catarrhal-atrophic, granulomatous (also known as hypertrophic) and sclerotic. The diagnosis is made either by positive Klebsiella rhinoscleromatis culture or from the classic histological findings of Mikulicz cells and transformed plasma cells with Russell bodies. Rhinoscleroma is endemic to areas of Africa, South-East Asia, Mexico, Central and South America, and Central and Eastern Europe, and it has been associated with low socioeconomic status. In the past, rhinoscleroma was infrequent in the US population but, with current trends in migration, the incidence of rhinoscleroma may be on the rise. There is often a delay in diagnosis in non-endemic areas such as the US due to unfamiliarity with the disease, the stage-dependent clinical and histological manifestations of disease, and the fact that only 50-60 per cent of cultures are positive for K rhinoscleromatis. Such late diagnosis leads to increased morbidity in the form of nasal and airway obstruction and nasal deformity from erosive processes. Rhinoscleroma is difficult to cure and prone to recur. Currently, the recommended treatment consists of a combination of surgical debridement and long-term antibiotic therapy. We present a case report of a culture-positive diagnosis of rhinoscleroma, and we review the existing literature.

show abstract

“…However, they have suggested methods to control nasal dryness by using lubricants or methods to decrease evaporation from the mucosal surface. Some studies have tried antibiotics with limited success 11 . The variable responses to different treatment regimes are due to the multifactorial nature of this disease 12,13 .It does not respond to any particular modality of treatment targeting a speci c etiology.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Atrophic Rhinitis with Manuka Honey–a non-randomized control trial, and a new theory of etiopathogenesis for the disease.

Sarkar

Purkait

Maiti

et al. 2021

Preprint

View full text Add to dashboard Cite

Exact etiology of Atrophic rhinitis (AtR) is yet unknown. Polygenic and polybacterial causes have been implicated in the onset and progression of this disease. AtR doesn’t respond to any particular modality of treatment that targets specific etiology, this describes its multifactorial nature. In this study, we report on a non-randomized control trial on the use of a nasal spray of 10% Manuka honey in patients with AtR attending the out-patient unit of the Department of Otorhinolaryngology and Head Neck Surgery. In this study, we show significant observations: 1. Decreased fetid smell, 2. Thickening of the mucosa, 3. Decreased inflammation with healed mucosal ulcers, 4. Increased concentration of the mucosal glands, 5. Alteration in Nasal microbiome, and 6. Increased expression of SCFA receptors. These changes occurred in response to honey therapy, and are consequent to the resetting of the Nasal microbiome.

show abstract

Ciprofloxacin for rhinoscleroma and ozena

Cited by 29 publications

References 4 publications

Rhinoscleroma: eight Peruvian cases

Rhinoscleroma: eight Peruvian cases

Klebsiella rhinoscleromatis of the membranous nasal septum

Treatment of Atrophic Rhinitis with Manuka Honey–a non-randomized control trial, and a new theory of etiopathogenesis for the disease.

Contact Info

Product

Resources

About